GLPwatch
First Reported Case of Dulaglutide-Induced Acute Pancreatitis With Normal Serum Lipase Level.
Cureus · 2023
Last updated 2026-05-28A case report describes a patient taking dulaglutide who showed signs of acute pancreatitis but had normal lipase levels in their blood. The authors suggest that doctors should consider acute pancreatitis even when lipase levels are normal and may need imaging tests to confirm the diagnosis.
AI summary of the abstract below.
| Journal | Cureus, 2023 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.44 |
| NIH percentile | 26 |
| Molecules | dulaglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
Dulaglutide is being extensively used for non-insulin-dependent diabetes mellitus and congestive heart failure and is also being used as an off-label weight loss aid. Due to its wide use, we had to shed some light on this rare finding of normal lipase level in a patient with signs and symptoms suggestive of acute pancreatitis. A high index of clinical suspicion for acute pancreatitis despite normal lipase should warrant a low threshold for radiological imaging to rule it out.
Verbatim abstract via PubMed 37465801 ↗
Related research
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
- Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
- Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).